Drug intelligence / Profile preview

Microdacyn Wound Care

Development stage
Unknown
Lead developer
Sonoma Pharmaceuticals
Administration
Topical
01

Overview

Microdacyn Wound Care is a super-oxidized solution (SOS) intended for the debridement, irrigation, and moistening of acute and chronic wounds, including ulcers, cuts, abrasions, and burns. Developed by Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences), it is a pH-neutral, non-cytotoxic medical device composed of electrolyzed water containing hypochlorous acid (HOCl) and sodium hypochlorite. The solution acts by reducing microbial load through oxidative damage to microbial cell walls and inhibiting biofilm formation, while maintaining a moist environment conducive to tissue regeneration. It is designed to mimic the body's natural immune response (phagocytosis) without damaging healthy human tissue. In regions like New Zealand and Australia, it is distributed by Te Arai BioFarma and is registered as a Class IIb medical device.

Brand names
MicrodacynMicrodacyn60Microdacyn-60Microdacyn 60Microdacyn Wound Care
Other names
super-oxidized solutionSOSelectrolyzed water
02

Targets

Chitin

Beyond the preview

Go deeper on Microdacyn Wound Care.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microdacyn Wound Care.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call